CVR College of Engineering

Selecta Biosciences Announces Merger with Cartesian Therapeutics

Retrieved on: 
Monday, November 13, 2023

and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.

Key Points: 
  • and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.
  • In connection with the merger, Selecta announced a $60.25 million private financing led by Timothy A. Springer, Ph.D., member of the Selecta Board of Directors.
  • Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc.
  • Selecta and Cartesian will host a conference call today, Monday, November 13, 2023, at 9:00 am ET to discuss the merger.

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

Retrieved on: 
Thursday, August 31, 2023

“We believe the proposed merger offers a unique and critical opportunity for Surface stockholders--the benefits are clear,” commented Rob Ross, MD, President and Chief Executive Officer. “The stock for stock transaction, valued at up to $65 million when announced, represents an approximate three-fold premium over our anticipated net cash at closing. Shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing.”

Key Points: 
  • CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have recommended Surface stockholders vote “FOR” the adoption of Surface’s merger agreement (the “merger agreement”) with Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”).
  • ISS and Glass Lewis are the leading independent, third-party proxy advisors to thousands of institutional investors and pension funds.
  • Both advisory firms believe the proposed adoption of the merger agreement presents the greatest opportunity for stockholders of Surface to realize value.
  • “We believe the proposed merger offers a unique and critical opportunity for Surface stockholders--the benefits are clear,” commented Rob Ross, MD, President and Chief Executive Officer.

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Retrieved on: 
Thursday, August 31, 2023

Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.

Key Points: 
  • Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.
  • In addition, Zevra has agreed to provide Acer with a bridge loan facility for up to $16.5 million, subject to certain terms and conditions.
  • The merger is expected to expand Zevra's rare disease portfolio, as well as increase and diversify its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs.
  • Pillsbury Winthrop Shaw Pittman LLP served as legal advisor to Acer, and William Blair & Company, LLC served as exclusive financial advisor to Acer.

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

Retrieved on: 
Monday, August 28, 2023

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points: 
  • Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
  • As a result, Pardes stockholders that tender their shares in the Offer will receive (i) $2.13 per share and (ii) one non-transferable CVR per share in accordance with the terms of the Offer.
  • Pardes’ stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation Statement, the Schedule 13E-3 and other filed documents for free at the SEC’s website at www.sec.gov .
  • In addition, Pardes’ stockholders may obtain free copies of the Offer materials by contacting Innisfree M&A Incorporated, the information agent for the Offer.

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

Retrieved on: 
Thursday, August 17, 2023

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points: 
  • Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
  • Pursuant to the terms of the Merger Agreement, Parent, Purchaser and Pardes have determined that the Additional Price Per Share, based on Pardes’ expected net cash, is $0.11 per share.
  • Accordingly, the total cash amount that Purchaser will pay pursuant to the terms of the Offer and the Merger Agreement is $2.13 per share.
  • Stockholders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the determination of the Additional Price Per Share or extension of the Offer expiration date.

Coherus to Acquire Surface Oncology

Retrieved on: 
Friday, June 16, 2023

– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –

Key Points: 
  • – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –
    – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affirms prior FY 2023 revenue and expense guidance –
    REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
  • With the agreement to acquire Surface and the expected near-term approval of toripalimab, Coherus is positioned to become one of the very few I-O companies with demonstrated commercial expertise, significant product revenues, and unique, competitively positioned R&D programs addressing critical unmet medical needs,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus.
  • Novel I-O clinical development will extend Coherus’ reach in oncology and expand physician experience with toripalimab.
  • The press release and live webcast of the conference call can be accessed through a link that is posted on Investors section of the Coherus website: https://investors.coherus.com/ and Investors section of the Surface Oncology website: https://investors.surfaceoncology.com/.

Coherus to Acquire Surface Oncology

Retrieved on: 
Friday, June 16, 2023

– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –

Key Points: 
  • – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –
    – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affirms prior FY 2023 revenue and expense guidance –
    REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
  • With the agreement to acquire Surface and the expected near-term approval of toripalimab, Coherus is positioned to become one of the very few I-O companies with demonstrated commercial expertise, significant product revenues, and unique, competitively positioned R&D programs addressing critical unmet medical needs,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus.
  • Novel I-O clinical development will extend Coherus’ reach in oncology and expand physician experience with toripalimab.
  • The press release and live webcast of the conference call can be accessed through a link that is posted on Investors section of the Coherus website: https://investors.coherus.com/ and Investors section of the Surface Oncology website: https://investors.surfaceoncology.com/ .

EQS-News: Steinhoff International Holdings N.V. : Notice of Annual General Meeting

Retrieved on: 
Monday, February 13, 2023

Steinhoff International Holdings N.V. (the “Company” or “Steinhoff”) disclosed on 2 February 2023 that the Company had been delayed in publishing the notice of the annual general meeting and shareholder circular while it sought certain regulatory confirmations, and that as a result the date of the AGM would be rescheduled.

Key Points: 
  • Steinhoff International Holdings N.V. (the “Company” or “Steinhoff”) disclosed on 2 February 2023 that the Company had been delayed in publishing the notice of the annual general meeting and shareholder circular while it sought certain regulatory confirmations, and that as a result the date of the AGM would be rescheduled.
  • The Company accommodates its shareholders (the “Shareholders”) in attending the AGM virtually through electronic means, without the need to physically attend the AGM.
  • Participating virtually in the AGM is subject to the Company’s hybrid meeting policy which is available on the Company’s website ( www.steinhoffinternational.com ).
  • Copies of the Notice, agenda and explanatory notes thereto, including the appendices and other meeting documents, are provided upon request and free of charge.

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

Retrieved on: 
Tuesday, February 7, 2023

Additionally, the Competition and Markets Authority in the United Kingdom has elected to take no action with regard to the proposed merger.

Key Points: 
  • Additionally, the Competition and Markets Authority in the United Kingdom has elected to take no action with regard to the proposed merger.
  • The proposed merger remains subject to approval by Opiant stockholders.
  • Indivior and Opiant continue to anticipate completing the Agreement in the first quarter of 2023.
  • The Opiant Board of Directors unanimously recommends that stockholders vote “FOR” the approval and adoption of the Agreement and the approval of the acquisition.

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

Retrieved on: 
Monday, February 6, 2023

The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC).

Key Points: 
  • The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC).
  • Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Opiant stockholders and the receipt of remaining applicable regulatory approvals.
  • Indivior and Opiant continue to anticipate completing the merger agreement in the first quarter of 2023.
  • The Opiant Board of Directors unanimously recommends that stockholders vote “FOR” the approval and adoption of the Agreement and the approval of the acquisition.